H.C. Wainwright Remains a Buy on Adaptimmune Therapeutics (ADAP)
Adaptimmune Therapeutics (NASDAQ:ADAP) Investors Are Sitting on a Loss of 86% If They Invested Five Years Ago
Insider Sale: Chief Medical Officer of $ADAP (ADAP) Sells 5,584 Shares
Adaptimmune Announces U.S. FDA Breakthrough Therapy Designation Granted to Letetresgene Autoleucel (Lete-cel) for Treatment of Myxoid/Round Cell Liposarcoma (MRCLS)
European Equities Traded in the US as American Depositary Move Slightly Lower in Thursday Trading
Adaptimmune Says CFO, Other C-Suite Officer to Step Down
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
